Biogen Fights $55M Claim Over Nerve Pain Drug Co. Payout
Biogen has hit back against a $55 million claim from the former shareholders of a U.K.-based drug company Convergence Pharmaceuticals, saying its nerve pain medication fell short of the required targets...To view the full article, register now.
Already a subscriber? Click here to view full article